Janux Therapeutics (JANX) said Monday that initial results from its phase 1 study of JANX011 in healthy volunteers showed deep B-cell depletion, grade 1-only cytokine release syndrome, and selective activation of the intended TRBV6-expressing T-cell subset after a single subcutaneous dose without step-up dosing.
At the 3 mg dose, three of five participants achieved more than 90% B-cell depletion, including two whose B-cell counts fell below the limit of detection, with reductions persisting through Day 42.
JANX011 is the first program from Janux's proprietary Adaptive Immune Response Modulator, or ARM, platform to enter clinical development. The platform is designed to recruit a defined T-cell subset to drive deep and sustained target-cell depletion while limiting broad T-cell activation.
No serious adverse events or dose-limiting toxicities were reported among the 25 participants, while other treatment-related adverse events were predominantly grade 1. Janux said one participant had a grade 3 ALT elevation and grade 2 ALT and AST elevations at the 3 mg dose.
Janux said it intends to advance JANX011 into autoimmune disease studies, initially targeting immune thrombocytopenia in the first half of 2027 and rheumatoid arthritis in the second half.
The company's shares fell more than 22% in early Monday trading.
Price: 13.73, Change: -3.90, Percent Change: -22.12